Guiding Oncology Therapies from Early Detection of Response to Approval.

Your Precision
Oncology CRO™

We are the leading oncology CRO, developing novel treatments for patients that need them most. Our team is fully dedicated to oncology – it is all we do – combining innovation and expertise to quickly move your medicines from preclinical development into clinical trials. Adaptive and forward-thinking – we guide your therapy through the most critical development milestones from the lab to planning your regulatory and clinical strategy. Our ultimate goal? To help patients.

We have you covered
throughout every phase.

Clinical Study Management

We offer Phase I, II and III clinical trial design, planning and execution utilizing a data-driven, flexible and efficient approach. Using innovative and precise methods for capturing and analyzing data, we identify early signals of response to put your oncology therapy on the path to approval.

Preclinical

In the early phase of oncology research, TD2 sets you up for success with an extensive suite of preclinical tools, over 400 models of cancer as well as extensive knowledge in designing and adapting your study to maximize data value and predict patient response.

Regulatory Support

Your medicine’s journey to approval requires a veteran team dedicated to navigating each phase of development. At TD2, we manage the most complex aspects of the regulatory process including IND readiness assessment, program evaluation, IND development and filings, and all FDA interactions.

PK/ADME

Drug metabolism and pharmacokinetic (DMPK) analyses are key to successful drug development and approval, and TD2 can help determine which tests are the best fit early through a diverse set of assays to support your program.

About TD2

Accelerating cancer treatments.

Since 2003, TD2 has made an impact beyond what is expected of a traditional oncology CRO. Not only do we work with hundreds of biotech and pharma companies to rapidly move new treatments to market through proactive problem solving and strategic collaboration, but we are also drug development innovators. The breadth of our services gives us the unique ability to translate scientific hypotheses generated in a lab setting into patient responses in the clinic. Our results consistently outpace our competition due to a dynamic, flexible and highly specialized team that is laser-focused on oncology.

News & Events

Press Release November 24, 2020
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)
Event October 30, 2020
Virtual J. P. Morgan Speaking Engagement: Data Driven and A.I. Enabled Clinical Solutions to Enhance Cancer Patient Outcomes
Press Release October 29, 2020
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices

Resources

Clinical September 30, 2020
The Trends Behind Successful Cancer Treatments
Preclinical September 30, 2020
CAR T-Cell Therapy: Revolutionizing Cancer Treatment
Clinical September 30, 2020
Data Insights: Identifying Early Signs of Safety and Efficacy in Oncology Clinical Trials

Blog

Clinical June 05, 2018
Move your research forward, smarter with TD2
Clinical August 20, 2018
The Top 5 Challenges in Oncology Drug Development
Preclinical November 14, 2019
Maximizing Reproducibility in Cancer Research

Contact Us

Work with a team who believes in
your research as much as you do.

Are you ready to move your cancer therapy to market? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.

Subscribe to the TD2 Newsletter.

Thank you.

Your request has been submitted. A member of our team will reach out to you shortly.

Move your research forward, smarter.